Teva Pharmaceutical Industries (NYSE: TEVA) announced Wednesday September 2, 2026 positive topline results from the ongoing Phase 2a study of TEV-408 (an investigational anti-interleukin-15 monoclonal antibody) in adults with celiac disease already following a gluten-free diet. The 50-patient study met its primary endpoint by demonstrating statistically significant and clinically substantive prevention of gluten-induced intestinal damage versus placebo at Week 8. Key efficacy: LS mean change from baseline in intraepithelial lymphocyte (IEL) density was +27.60 for placebo versus +0.37 for TEV-408 (treatment difference -27.23, 95% CI: -39.67 to -14.79). TEV-408 also demonstrated lower gastrointestinal symptom scores versus placebo on the patient-reported Celiac Disease Symptom Diary. Safety was clean with no signals observed. TEV-408 received FDA Fast Track designation in May 2025 and represents a novel mechanism in celiac disease where no disease-modifying therapies are approved and standard-of-care remains strict gluten-free diet adherence. Teva positioned the win as further validation of its 'pipeline-in-a-product' anti-IL-15 platform strategy.
BioXcel Therapeutics (NASDAQ: BTAI) filed for Chapter 11 bankruptcy protection Thursday August 27, 2026 after telling investors it lacked cash to fund operations through the end of August despite securing a bridge loan earlier the same week. Teva Pharmaceutical Industries (NYSE: TEVA) signed a stalking-horse asset sale agreement Friday August 28, 2026 to acquire BioXcel's lead neuroscience asset for $57.5 million upfront plus up to $67.5 million in milestone payments through a court-supervised auction. The lead asset is a novel dexmedetomidine sublingual film under FDA review for at-home use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, with a PDUFA target action date of November 14, 2026. The stalking-horse bid sets the floor price for competing bidders. Teva positioned the acquisition as consistent with its 'Pivot to Growth' strategy and disciplined business development approach.
President Donald Trump announced Tuesday July 21, 2026 via social media that imported generic drugs will face zero tariffs for two years starting August 1, 2026 before a 100% levy takes effect in August 2028 and rises to 200% one year later. Trump described the escalation as 'a penalty' for companies that do not build manufacturing plants in the US within the grace period. India is the largest exporter of generic medicines to the US ($10.5 billion in fiscal year 2024-25), with pharmaceuticals among India's top three exports to America. Companies with the greatest exposure include Teva, Viatris, and Apotex, all of which manufacture a large share of US-sold products overseas. Sandoz (Novartis' generic subsidiary), which had two Abbreviated New Drug Applications for generic tirzepatide (Mounjaro and Zepbound) accepted by the FDA on June 29, 2026, told CNBC it was 'too early to assess' the proposal because 'further details on the implementation and scope of the measure are still required.' The tariff timeline collides with the tirzepatide patent expiration (2036 in the US) and the Indian generic semaglutide launches from Biocon, Dr. Reddy's, and Hetero that rolled out in March-April 2026. Patented and branded drugs remain unchanged under the April 2 Section 232 100% patented pharma tariff.